Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 14/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492615 | 0.95 | CXCR3 (0.41) | CXCR3BDKRB1PTGIRALDH1A1LMNA | |
| SCHEMBL493291 | 0.95 | CXCR3 (0.41) | CXCR3BDKRB1PTGIRLMNA | |
| SCHEMBL492554 | 0.94 | CXCR3 (0.40) | CXCR3BDKRB1PTGIRALDH1A1LMNA | |
| SCHEMBL493441 | 0.91 | AVPR1A (0.40) | CXCR3PTGIRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL492295 | 0.90 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL493107 | 0.90 | BDKRB1 (0.42) | BDKRB1 | |
| SCHEMBL493132 | 0.89 | BDKRB1 (0.41) | CXCR3BDKRB1 | |
| SCHEMBL493391 | 0.89 | BDKRB1 (0.41) | CXCR3BDKRB1PTGIRLMNA | |
| SCHEMBL493271 | 0.89 | CXCR3 (0.44) | CXCR3BDKRB1PTGIR | |
| SCHEMBL492523 | 0.88 | BDKRB1 (0.40) | CXCR3BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CXCR3 4458/4885BDKRB1 1622/4885PTGIR 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.